Tech Company Financing Transactions
AXONIS Therapeutics Funding Round
AXONIS Therapeutics, based in Cambridge, scored $115 million in investment from Cormorant Asset Management, venBio Partners and Lumira Ventures.
Transaction Overview
Company Name
Announced On
10/30/2024
Transaction Type
Venture Equity
Amount
$115,000,000
Round
Series A
Investors
Cormorant Asset Management (Lead Investor)
venBio Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for inhibitory neurotransmission, for the treatment of epilepsy and pain.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
700 Main St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
AXONIS Therapeutics is advancing breakthrough drug discovery to develop groundbreaking therapies for spinal cord injury, and other currently incurable neurological disorders, making a real difference for patients, their families, and global healthcare system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joanna Stanicka
Chief Scientific Officer
Shane Hegarty
Browse more venture capital transactions:
Prev: 10/30/2024: iGent AI venture capital transaction
Next: 10/30/2024: Toothio venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs